细胞穿膜肽抗人膀胱癌单克隆抗体载丝裂霉素白蛋白纳米微球三联体的靶向性和穿膜活性研究-东南大学学报医学版

细胞穿膜肽抗人膀胱癌单克隆抗体载丝裂霉素白蛋白纳米微球三联体的靶向性和穿膜活性研究

单位：1. 江苏大学附属昆山医院泌尿外科, 江苏昆山 215300;
2. 苏州大学附属第一医院泌尿外科, 江苏苏州 215000;
3. 广西医科大学第一附属医院泌尿外科, 广西南宁 530021

分类号：R737.14;R73-36

出版年·卷·期（页码）：2014·33·第一期（49-53）

摘要：

目的：探讨细胞穿膜肽（TAT-EGFP）-抗人膀胱癌单克隆抗体（BDI-1）-载丝裂霉素白蛋白纳米微球（MMC-NS）三联体的靶向性和穿膜活性。方法：采用异型双功能连接剂SPDP，偶联TAT-EGFP、BDI-1、MMC-NS形成三联体偶联物，进行EJ人膀胱癌靶向结合及穿膜试验，通过激光共聚焦、扫描电子显微镜及透射电子显微镜检测其靶向结合特异性和穿膜活性。结果：成功地应用异型双功能连接剂SPDP偶联TAT-EGFP、BDI-1、载MMC白蛋白纳米微球制成三联体。TAT-EGFP-BDI-1-MMC-NS偶联物能够成功进入细胞发挥细胞毒作用。首次发现TAT-EGFP内化MMC-NS入EJ人膀胱癌细胞内部后微绒毛消失的现象。结论：TAT-EGFP-BDI-1-MMC-NS三联体有可能应用于膀胱肿瘤的靶向治疗。

Objective: evaluation the ability of targeting and transmembrane activity of the triad of cell penetrating peptides-human bladder cancer monoclonal antibody conjugated with MMC-loaded albumin nanoparticle. Methods: To target and penetrate bladder cancer cell by TAT-EGFP-BDI-1-MMC-NS triplet conjugate (heter-bifunctional cross-linking agent SPDP,cell-penetrating peptides TAT-EGFP, human bladder cancer monoclonal antibody BDI-1 and MMC-loaded albumin nanoparticle) and to test its ability of specific binding and transmembrane activity using diaminofluorescein, under transmission electron microscope, transmission electron microscopy. Results: We succeeded in using heterbifunctional cross-linking agent SPDP,cell-penetrating peptides TAT-EGFP,human bladder cancer monoclonal antibody and MMC-loaded albumin nanoparticle to couple and form triplet conjugate(TAT-EGFP-BDI-1-MMC-NS).The triad of cell penetrating peptides-human bladder cancer monoclonal antibody conjugated with MMC-loaded albumin nanoparticle suggested good cytotoxic effect on human bladder cancer cells. It was the first time to show the dependencies cancer cell membrane surface showed with microvilli disappearance after albumin nanoparticles entering cancer cells. Conclusion: This study suggested that the triad of cell penetrating peptides-human bladder cancer monoclonal antibody conjugated with MMC-Loaded Albumin Nanoparticle have potential feasibility in targeting therapy for bladder cancer.

参考文献：

[1] FOMECA S B, PEMIM M P, KELLEY S O.Recent advances in the use of cell-penetrating peptides for medical and biological applications[J].Adv Drug Deliv Rev, 2009, 61(11):953-964.
[2] NOGUCHI H, MATSUMOTO S.Protein transduetion technology:a novel therapeutic perspective[J].Acta Med Okayama, 2006, 60(1):1-11.
[3] 熊梦华, 杜金志, 王均.聚磷酸酯纳米凝胶载药系统的研究进展[J].东南大学学报:医学版, 2011, 30(1):262.
[4] ZHOU J, ZENG F, GAO X, et al.Preparation of arsenic trioxide albo-rain mlcrespheres and the release characteristics in vitro[J].J Huazhong Univ Sei Technolog Med Sci, 2005, 25(3):310-312.
[5] 戚宁, 杜明华, 张东生, 等.制备单抗偶联载阿霉素白蛋白免疫毫微球的初步研究[J].东南大学学报:医学版, 2012, 31(4):393.
[6] KHANDRE J J, MINKO T.Antibodies and peptides in csrlcer therapy[J].Crit Rev Ther Drug Carrier Syst, 2006, 23(5):401-435.
[7] 陈猛, 郝林, 韩从辉, 等.双调控溶瘤腺病毒携带PM5基因靶向鼠膀胱癌的表达[J].东南大学学报:医学版, 2012, 31(2):167.
[8] 吴天麟, 张俊杰, 王甫剑, 等.吡柔比星膀胱内灌注防治浅表性膀胱癌术后复发(附73例报告)[J].东南大学学报:医学版, 2006, 25(2):114.
[9] 马爱红, 俞莉章, 谢蜀生, 等.抗人膀胱癌单克隆体BIU-87的制备和鉴定[J].中华泌尿外科杂志, 1990, 11(4):195-198.
[10] HERMANSON G T.Biocenjugate Techniques[M].2nd ed.San Diego:Academic Press, 2008:277-335.
[11] SURASH S, NEMETH P, CHAKRAKRABARTY A, et al.The conjugation of an AQPI-directed immunotoxin in the study of site-directed therapy within the CNS[J].Childs Nerv Syst, 2011, 27(5):811-818.
[12] ZHOU J, ZENG F, LI C, et al.Preparation of arsenic trioxide loaded albumin immuno-nanospheres and its sveeifie killingeffect on bladder cancer cell in vitro[J].Chin Med J, 2005, 118(1):50-55.
[13] 阚和平, 刘正军, 谭永法, 等.抗人肝癌免疫毫微球的制备及其抗癌效果观察[J].南方医科大学学报, 2008, 28(8):1503-1505.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录